Navigation Links
TransCelerate BioPharma Inc. Takes Steps Toward Common Clinical Trial Site Qualification & Training
Date:6/20/2013

We look forward to continuing our work with TransCelerate to find other pre-competitive opportunities that will aid the sites, and thereby the industry. It is a true milestone that industry is listening to the sites and taking action like this."

Now that the SQT initiative has achieved these near-term goals, the initiative will move into its second phase, where member companies are continuing to realize efficiencies around pre-qualification efforts such as common oversight measures, training and forms, and assessing the benefits of a common comprehensive framework for investigator/staff and site prequalification.

A list of TransCelerate member companies and their acceptable minimum criteria for GCP training, as well as common forms for investigator CVs and site-specific profile information, can be found at the link under "Site Qualification and Training" here.

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. was formed in 2012 and is a non-profit organization focused on advancing innovation in research and development (R&D), identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. TransCelerate evolved from discussions at various forums for executive R&D leadership to discuss relevant issues facing the industry and solutions for addressing common challenges. Founding members include AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi, and all have representation on the Board of Directors. Additional members include Astellas Pharma Inc., Biogen Idec, Braeburn Pharmaceuticals, EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Forest Research Institute (a subsidiary of Forest Laboratories, Inc.) and On
'/>"/>

SOURCE TransCelerate BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
2. Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes
3. PDL BioPharma Announces First Quarter 2013 Financial Results
4. Array BioPharma to Present at the Bank of America Merrill Lynch Healthcare Conference and the UBS Global Healthcare Conference
5. PDL BioPharma Appoints Peter Garcia as Chief Financial Officer
6. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
7. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
8. Biotechnology Market (Biopharmacy, Bioservices, Bioagri, Bioindustrial) Is Expected to Reach USD 414.5 Billion Globally in 2017: Transparency Market Research
9. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
10. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
11. Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... ... bring together supply chain risk management and resiliency practitioners with luminaries and thought ... best practices, and be recognized for their innovations and performance excellence. At that ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced the ... Growth, Trends & Forecasts (2014-2020)" report to their ... is estimated at $0.17 billion by 2018 at a ... The near future will bring Biomedical sensors that are ... sensors can be set to trigger alerts when unpredictable ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... Calif. and SHANGHAI ... a privately-held biopharmaceutical company developing next-generation antibiotics, today ... 2 clinical study for its lead drug candidate ... to treat drug-resistant bacteria such as MRSA and ... and better tolerated therapeutic option than currently available ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2
... June 24 The Board of,Directors of Schering-Plough Corporation ... 6.5 cents per common share. Payment will be made ... close of business on Aug.,1, 2008. As of March ... Board of Directors today also declared a quarterly dividend ...
... Sun Pharmaceutical,Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: ... Levitt, Chairman of the Board,of Directors of Taro Pharmaceutical ... Levitt,s letter of June 19, 2008 to Taro,s,shareholders, his ... the Initiating,Motion filed by Taro in the Tel-Aviv District ...
... etiquette tips via live, interactive ... ... a new way for life science post graduates to enhance their skills,and ... a dual-purpose service that,provides employers a chance to meet potential candidates, and ...
Cached Biology Technology:Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 2Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 3Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 4Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 5Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 6Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary 7Online Career Tool Offers Live 'Expert Advice' Component 2
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... has comparable efficacy to chemotherapy, and is better ... has progressed quickly after treatment with first-line therapy, ... show. Dr Tudor Ciuleanu from the Institute ... finding from the international TITAN study at the ...
... have found that when growing corn crops for ethanol, more ... edition of the American Chemical Society,s journal Environmental Science ... fertilizer while they improve their production of feedstock for ethanol ... implications for an industry that has grown dramatically in recent ...
... York University,s Clinical and Translational Science Institute (CTSI) has ... grant to assess the feasibility of using gingival crevicular ... a blood glucose measurement -- as a means of ... between New York University,s Langone Medical Center and the ...
Cached Biology News:Erlotinib effective and with fewer side-effects after first-line treatment 2Overfertilizing corn undermines ethanol 2Overfertilizing corn undermines ethanol 3NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 2NYU nursing-dental team receives grant to assess effectiveness of A1C diabetes screening technique 3
... The UltraRocker rocking platform, 120 V, is ... overnight incubation of liquid cultures, staining and destaining ... rocker features variable speed control (8-40 rpm) and ... (10 lb). The rocker features two 29 x ...
Mouse monoclonal antibody to DCAMKL2 - doublecortin and CaM kinase-like 2...
...
...
Biology Products: